EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Tirzepatide for obesity without diabetes: mechanistic insights, clinical evidence, and future directions

Wen-Ting He, Yi-Di Song, Xin-Yu Wang, Si-Yuan He, Xue Tao, Shi-Xuan Yuan, Liang Zhou, En-Wu Long

Frontiers in Pharmacology · 18.08.2026 · 17

DOI: 10.3389/fphar.2026.1889594 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 18.08.2026. Verfasst von Wen-Ting He und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Institute of Laboratory Animal Sciences, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and…. Die Arbeit nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity and its related complications have become an important public health concern. Traditional lifestyle modification and earlier pharmacotherapies provide only limited weight reduction. There is an urgent need for more effective treatments. Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist (GIP/GLP-1 RA). Its distinctive pharmacological mechanisms and outstanding effects on weight loss have attracted wide attention. Although initial studies on tirzepatide mainly focused on type 2 diabetes mellitus (T2DM), evidence in adults with obesity without T2DM has expanded rapidly. Available human evidence supports reduced appetite and energy intake as major contributors to weight reduction, whereas mechanisms involving central neural circuits, adipose-tissue remodeling, and biased receptor signaling remain largely preclinical or translational. In available clinical trials, tirzepatide has been shown to produce substantial weight reduction and appears to be among the most effective obesity management medications (OMMs), although most comparisons beyond SURMOUNT-5 remain indirect. Its safety profile is characterized mainly by mild-to-moderate gastrointestinal symptoms during dose escalation, while long-term and rare safety outcomes require continued evaluation. In this narrative review, we summarize the mechanisms, clinical efficacy, safety, comparative positioning, and evidence gaps relevant to long-term real-world evaluation and next-generation incretin-based therapies.

Schlagwörter

Stichwörter der Autor:innen

efficacyfuture directionsmechanismobesitysafetytirzepatide

Autor:innen und Institutionen

  • Department of Institute of Laboratory Animal Sciences, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
  • Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chen…
  • School of Pharmacy of Southwest Medical University, Luzhou, Sichuan, China.

Zitieren

APA

He, W. T., Song, Y. D., Wang, X. Y., He, S. Y., Tao, X., Yuan, S. X., Zhou, L., & Long, E. W. (2026). Tirzepatide for obesity without diabetes: mechanistic insights, clinical evidence, and future directions. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1889594

Vancouver

He WT, Song YD, Wang XY, He SY, Tao X, Yuan SX, et al. Tirzepatide for obesity without diabetes: mechanistic insights, clinical evidence, and future directions. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1889594

BibTeX
@article{He2026,
  author = {He, Wen-Ting and Song, Yi-Di and Wang, Xin-Yu and He, Si-Yuan and Tao, Xue and Yuan, Shi-Xuan and Zhou, Liang and Long, En-Wu},
  title = {Tirzepatide for obesity without diabetes: mechanistic insights, clinical evidence, and future directions},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1889594}
}
Kostenlos starten →